Advanced Non-small Cell Lung Cancer with Acquired RET Fusion After ALK-TKI Resistance: A Case Report and Literature Review
-
-
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：李锦华：文献查阅及论文撰写祁 萍：图片整理及论文校对乔 慧：论文指导、审阅与修改
-
![]()
图 1 应用ALK抑制剂及RET抑制剂治疗前后病灶变化
Figure 1 Efficacy and progression before and after treatment with ALK and RET inhibitors
-
[1] Zhang K, Chen H, Wang Y, et al. Clinical characteristics and molecular patterns of retrearranged lung cancer in chinese patients[J]. Oncol Res, 2019, 27(5): 575-582.
[2] 马兰兰, 李卉. RET融合阳性非小细胞肺癌研究进展[J]. 癌症, 2022, 41(8): 345-353. [Ma LL, Li H, Research progress in RET fusion-positive non-small cell lung cancer[J]. Ai Zheng, 2022, 41(8): 345-353.] Ma LL, Li H, Research progress in RET fusion-positive non-small cell lung cancer[J]. Ai Zheng, 2022, 41(8): 345-353.
[3] 张迪, 冉冬芝, 余瑜, 等. ALK抑制剂在NSCLC中的耐药机制及逆转策略的研究进展[J]. 中国药科大学学报, 2020, 51(6): 655-663. [Zhang D, Rang DZ, Yu Y, et al. Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC[J]. Zhongguo Yao Ke Da Xue Xue Bao, 2020, 51(6): 655-663.] doi: 10.11665/j.issn.1000-5048.20200603 Zhang D, Rang DZ, Yu Y, et al. Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC[J]. Zhongguo Yao Ke Da Xue Xue Bao, 2020, 51(6): 655-663. doi: 10.11665/j.issn.1000-5048.20200603
[4] Yu Y, Ou Q , Wu X, et al. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer[J]. Lung Cancer, 2019, 127: 19-24.
[5] Russo A, Cardona AF, Caglevic C, et al. Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies[J]. Transl Lung Cancer Res, 2020, 9(6): 2581-2598. doi: 10.21037/tlcr-2019-cnsclc-06
[6] Lipson D, Capelletti M, Yelensky R , et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies[J]. Nat Med, 2012, 18(3): 382384.
[7] Wang C, Zhang Z, Sun Y, et al. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer[J]. J Transl Med, 2022, 20(1): 390. doi: 10.1186/s12967-022-03593-3
[8] Zhang K, Chen H, Wang Y, et al. Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients[J]. Oncol Res, 2019, 27(5): 575-582. doi: 10.3727/096504018X15344979253618
[9] McCoach CE, Le AT, Gowan K, et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer[J]. Clin Cancer Res, 2018, 24(14): 3334-3347. doi: 10.1158/1078-0432.CCR-17-2452
[10] Zhao Z, Su C, Xiu W, et al. Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report[J]. JTO Clin Res Rep, 2022, 3(6): 100343.
[11] Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion[J]. Cancer Discov, 2018, 8(12): 1529-1539. doi: 10.1158/2159-8290.CD-18-1022
[12] Bronte G, Ulivi P, Verlicchi A, et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects[J]. Lung Cancer (Auckl), 2019, 10: 2736.
[13] 中国抗癌协会肿瘤精准治疗专业委员会, 中华医学会杂志社肺癌研究协作组, 中国临床肿瘤学会非小细胞肺癌专家委员会. 晚期RET融合阳性非小细胞肺癌诊疗中国专家共识(2023版)[J]. 中华肿瘤杂志, 2023, 45(12): 991-1002. [Society of Cancer Precision of Chinese Anti-Cancer Association, Lung Cancer Expert Group of Chinese Medical Journal, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer. Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2023, 45(12): 991-1002.] doi: 10.3760/cma.j.cn112152-20230711-00290 Society of Cancer Precision of Chinese Anti-Cancer Association, Lung Cancer Expert Group of Chinese Medical Journal, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer. Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2023, 45(12): 991-1002. doi: 10.3760/cma.j.cn112152-20230711-00290
[14] Terada T. Occult very small lung carcinoma with a solitary brain metastasis that is clinically diagnosed as cavernous hemangioma: a case report[J]. Cases J, 2009, 2: 7475. doi: 10.4076/1757-1626-2-7475
[15] 胡兰兰, 葛方明, 雷清, 等. 颅内海绵状血管瘤患者MRI、CT表现及诊断观察[J]. 中国CT和MRI杂志, 2022, 20(7): 25-26, 39. [Hu LL, Ge FM, Lei Q, et al. MRI and CT Manifestations and Diagnostic Value of Patients with Intracranial Cavernous Hemangioma[J]. Zhongguo CT He MRI Za Zhi, 2022, 20(7): 25-26, 39.] doi: 10.3969/j.issn.1672-5131.2022.07.008 Hu LL, Ge FM, Lei Q, et al. MRI and CT Manifestations and Diagnostic Value of Patients with Intracranial Cavernous Hemangioma[J]. Zhongguo CT He MRI Za Zhi, 2022, 20(7): 25-26, 39. doi: 10.3969/j.issn.1672-5131.2022.07.008
[16] 张贵斌, 李茂进, 陈喜兰, 等. 肺癌脑转移的临床表现和其MRI诊断价值[J]. 微循环学杂志, 2003, 13(2): 22-23, 25. [Zhang GB, Li MJ, Chen XL, et al. The Manifestation of Brain Metastases From Lung Cancer and the Value of MRI in Their Diagnosing[J]. Wei Xun Huan Xue Za Zhi, 2003, 13(2): 22-23, 25.] doi: 10.3969/j.issn.1005-1740.2003.02.010 Zhang GB, Li MJ, Chen XL, et al. The Manifestation of Brain Metastases From Lung Cancer and the Value of MRI in Their Diagnosing[J]. Wei Xun Huan Xue Za Zhi, 2003, 13(2): 22-23, 25. doi: 10.3969/j.issn.1005-1740.2003.02.010
[17] 刘洪武, 陈艳. 脑肿瘤卒中的发病机制与MRI表现[J]. 中国CT和MRI杂志, 2005, 3(3): 19-21. [Liu HW, Chen Y, et al. Pathogenesis and MRI features of stroke due to brain tumor[J]. Zhongguo CT He MRI Za Zhi, 2005, 3(3): 19-21.] doi: 10.3969/j.issn.1672-5131.2005.03.006 Liu HW, Chen Y, et al. Pathogenesis and MRI features of stroke due to brain tumor[J]. Zhongguo CT He MRI Za Zhi, 2005, 3(3): 19-21. doi: 10.3969/j.issn.1672-5131.2005.03.006
下载:
计量
- 文章访问数: 1280
- HTML全文浏览量: 543
- PDF下载量: 688
